Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Free Cash Flow (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Free Cash Flow data on record, last reported at $121.6 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 42.18% year-over-year to $121.6 million; the TTM value through Dec 2025 reached $327.6 million, up 59.96%, while the annual FY2025 figure was $327.6 million, 59.96% up from the prior year.
  • Free Cash Flow reached $121.6 million in Q4 2025 per COLL's latest filing, up from $79.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $121.6 million in Q4 2025 and bottomed at -$25.4 million in Q1 2022.
  • Average Free Cash Flow over 5 years is $51.5 million, with a median of $58.0 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: tumbled 226.22% in 2022, then surged 899.38% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at $35.7 million in 2021, then soared by 83.24% to $65.4 million in 2022, then grew by 11.91% to $73.2 million in 2023, then increased by 16.9% to $85.5 million in 2024, then surged by 42.18% to $121.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $121.6 million in Q4 2025, $79.0 million in Q3 2025, and $72.4 million in Q2 2025.